eb103
eb103: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Estrella Immunopharma Inc. (ESLA) | Phase 1/Phase 2 |
Clinical Trials (1)
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Frequently asked questions
Who is developing eb103?
eb103 is being developed by Estrella Immunopharma Inc..
How many clinical trials involve eb103?
BioSniper tracks 1 clinical trial involving eb103.
Get deeper analysis on eb103
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis